Advertisement

Journal of Neural Transmission

, Volume 113, Issue 6, pp 751–756 | Cite as

Functional effects of neuromelanin and synthetic melanin in model systems

  • K. L. Double
Article

Summary.

The function of the dark polymer pigment neuromelanin found in catecholaminergic neurons of the human brain is not understood, especially as most published data are based upon a synthetic model melanin which differs structurally to the native pigment. Nevertheless human neuromelanin has been shown to efficiently bind transition metals such as iron, as well as other potentially toxic molecules. The pigment may have a protective function in the healthy brain by, for example, contributing to iron homeostasis within pigmented nuclei. We have demonstrated that synthetic dopamine melanin stimulates cell damage in both cell lines and primary cells in vitro, an effect associated with increased hydroxyl radical production and apoptosis. In contrast, at low iron concentrations native neuromelanin does not induce cell damage but rather protects cells in culture from oxidative stress. This protective function appears to be lost at high iron concentrations where neuromelanin saturated with iron functions as a source of oxidative load, rather than an iron chelator. Changes to neuromelanin and tissue iron load in Parkinson’s disease may decrease the protective potential of the pigment, thus increase the potential for cell damage in this disorder.

Keywords: Melanin, neuroprotection, Parkinson’s disease. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aimi, Y, McGeer, PL 1996Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons ParkinsonRel Disord26974CrossRefGoogle Scholar
  2. Ben-Shachar, D, Riederer, P, Youdim, MBH 1991Iron-melanin interaction and lipid peroxidation: implications for Parkinson’s diseaseJ Neurochem5716091614PubMedGoogle Scholar
  3. Ben-Shachar, D, Youdim, MB 1990Selectivity of melanized nigra-striatal dopamine neurons to degeneration in Parkinson’s disease may depend on iron-melanin interactionJ Neural Transm [Suppl]29251258Google Scholar
  4. Berg, MD, Gerlach, M, Youdim, MBH, Double, KL, Zecca, L, Riederer, P, Becker, G 2001Brain iron pathways and their relevance to Parkinson’s diseaseJ Neurochem79225236PubMedCrossRefGoogle Scholar
  5. Bolzoni, F, Giraudo, S, Lopiano, L, Bergamasco, B, Fasano, M, Crippa, PR 2002Magnetic investigations of human mesencephalic neuromelaninBiochem Biophys Acta1586210218PubMedGoogle Scholar
  6. Double, K, Riederer, P, Gerlach, M 1999The significance of neuromelanin in Parkinson’s diseaseDrug News Develop12333340Google Scholar
  7. Double, K, Zecca, L, Costo, P, Mauer, M, Greisinger, C, Ito, S, Ben-Shachar, D, Bringmann, G, Fariello, RG, Riederer, P, Gerlach, M 2000Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melaninsJ Neurochem7525832589PubMedCrossRefGoogle Scholar
  8. Double, KL, Gerlach, M, Schünemann, V, Trautwein, AX, Zecca, L, Gallorini, M, Youdim, MBH, Riederer, P, Ben-Shachar, D 2003Iron binding characteristics of neuromelanin of the human substantia nigraBiochem Pharmacol66489494PubMedCrossRefGoogle Scholar
  9. Double, KL, Halliday, GM, Henderson, J, Griffiths, FM, Heinemann, T, Riederer, P, Gerlach, M 2003The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegenerationExp Neurol184530535PubMedCrossRefGoogle Scholar
  10. Fasano, M, Giraudo, S, Coha, S, Bergamasco, B, Lopiano, L 2003Residual substantia nigra neuromelanin in Parkinson’s disease is cross-linked to alpha-synucleinNeurochem Int42603606PubMedCrossRefGoogle Scholar
  11. Faucheux, BA, Martin, ME, Beaumont, C, Hauw, JJ, Agid, Y, Hirsch, EC 2003Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s diseaseJ Neurochem8611421148PubMedCrossRefGoogle Scholar
  12. Fedorow, H, Tribl, F, Halliday, G, Gerlach, M, Riederer, P, Double, KL 2005Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson’s diseaseProg Neurobiol75109124PubMedCrossRefGoogle Scholar
  13. Hirsch, E, Graybiel, A, Agid, Y 1988Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson’s diseaseNature28345348CrossRefGoogle Scholar
  14. Korytowski, W, Sarna, T, Zareba, M 1995Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidationArch Biochem Biophys319142148PubMedCrossRefGoogle Scholar
  15. Li, J, Scheller, C, Koutsilieri, E, Griffiths, F, Beart, PM, Mercer, LD, Halliday, G, Kettle, E, Rowe, D, Riederer, P, Gerlach, M, Rodriguez, M, Double, KL 2005Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cellsJ Neurochem95599608PubMedCrossRefGoogle Scholar
  16. Liu, Y, Hong, L, Kempf, V, Wakamatsu, K, Ito, S, Simon, J 2004Ion-exchange and adsorption of Fe2(III) by Sepia melaninPigment Cell Res17262269PubMedCrossRefGoogle Scholar
  17. Lopiano, L, Chiesa, M, Digilio, D, Giraudo, G, Bergamasco, B, Fasano, M 2000Q-band EPR investigations of neuromelanin in control and Parkinson’s disease patientsBiochem Biophys Acta1500306312PubMedGoogle Scholar
  18. Offen, D, Ziv, I, Barzilai, A, Gorodin, S, Glater, E, Hochman, A, Melamed, E 1997Dopamine-melanin induces apoptosis in PC12 cells; Possible implications for the etiology of Parkinson’s diseaseNeurochem Int31207216PubMedCrossRefGoogle Scholar
  19. Pilas, B, Sarna, T, Kalyanaraman, B, Swartz, H 1988The effect of melanin on iron associated decomposition of hydrogen peroxideFree Radic Biol Med4285293PubMedCrossRefGoogle Scholar
  20. Shima, T, Sarna, T, Swartz, H, Stroppolo, A, Gerbasi, R, Zecca, L 1997Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy studyFree Radic Biol Med23110119PubMedCrossRefGoogle Scholar
  21. Wilms, H, Rosenstiel, P, Sievers, J, Deuschl, G, Zecca, L, Lucius, R 2003Activation of microglia by human neuromelanin is NF-κB-dependent and involves p38 mitrogen-activated protein kinase: implications for Parkinson’s diseaseFASEB J17500502PubMedGoogle Scholar
  22. Youdim, M, Ben-Shachar, D, Riederer, P 1989Is Parkinson’s disease a progressive siderosis of substantia nigra resulting from iron and melanin induced neurodegeneration?Acta Neurol Scand1264754CrossRefGoogle Scholar
  23. Zareba, M, Bober, A, Korytowski, W, Zecca, L, Sarna, T 1995The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systemsBiochem Biophys Acta1271343348PubMedGoogle Scholar
  24. Zecca, L, Tampellini, D, Gatti, A, Crippa, R, Eisner, M, Sulzer, D, Ito, S, Fariello, R, Gallorini, M 2002The neuromelanin of the human substantia nigra and its interaction with metalsJ Neural Transm109663672PubMedCrossRefGoogle Scholar
  25. Zecca, L, Zucca, FA, Wilms, H, Sulzer, D 2003Neuromelanin of the substantia nigra: a neuronal block hole with protective and toxic characteristics TrendsNeurosci26578580Google Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • K. L. Double
    • 1
  1. 1.Prince of Wales Medical Research InstituteSydneyAustralia

Personalised recommendations